Abstract. A retrospective analysis was made of the parasitologic and fever records of 318
Previously of major public health importance in the Unit ed States and Europe, malaria is one of the most important parasitic diseases afflicting humans in the tropics. It contin ues to be the object of extensive biologic, pathologic, im munologic, and epidemiologic study.
Progress in the development of antimalarial vaccines and their eventual introduction into humans has emphasized our need to understand the natural development of immunity to this disease in individual patients, and the effect of prior infection with homologous and/or heterologous strains and species of Plasmodium on subsequent infections. Evaluation of the efficacy of vaccines in humans will be based on re ductions in asexual and sexual parasite counts and the fre quency and intensity of fever. The construction of the re� quired mathematical models for vaccine as well as cherifo therapeutic evaluation will depend on such parasitologic and clinical data. The primary source for information on the course of plasmodial infection in humans is archival data from the time when malariatherapy (the purposeful induction of malaria) was used to treat patients with neurosyphilis. Thus, a database has been extracted from parasitologic and fever records acquired between 1940 and 1963 at National Institutes of Health installations then located at the South Carolina State Hospital in Columbia, South Carolina, and the Georgia State Hospital in Milledgeville, Georgia.
An examination of these data was made to determine 1) the development of parasitologic and clinical immunity dur ing primary infection, 2) the effect on parasitemia and fever of prior infection with a homologous species of Plasmodium, 3) the effect of previous infection with heterologous species of Plasmodium on these parameters, and 4), the effect of previous infection on the frequency of recrudescence. The 4 latter is taken as an indication of the frequency at which new immunologically or antigenically variant populations of par asites emerge during the course of an infection. Such infor mation should allow for a better interpretation of the efficacy of candidate vaccines, and help to establish guidelines for their assessment in humans. Infections with P. Ja lciparum can be clinically severe and life-threatening. Thus, those time periods when high-density parasitemia and high fever are encountered during the course of natural infection will serve as guides for the assessment of candidate vaccines in volunteers.
Because development of P. Ja lciparum vaccines has the greatest priority, an assessment of the available data for this species of Plasmodium was initially prepared. However, sim ilar analyses of data from infections with P. vivax, P. ovale, and P. malariae are being made to provide information that should be useful when candidate vaccines for these infec tions are developed.
HISTORICAL PERSPECTIVE
Use of malariatherapy. Fever had long been thought to have a beneficial effect on various medical conditions. Ac cording to Becker, I Boisseau in 18322 advised "those afflict ed with epilepsy, gout, mania, and the paralytic should go to the Pontine Marshes, where they were certain to contract the fever and be remedied thereafter."
In 1917,3.4 Wagner-J auregg induced malaria for the first time to treat paresis. A soldier with tertian malaria (P. vivax) was admitted to the psychiatric clinic at the University Hos pital for Nervous and Mental Disease in Vienna, Austria in June 1917. Blood was passaged to 3 patients with "dementia * Patients were exposed by mosquito bite or the subcutaneous or intravenous inoculation (lnoc.) of sporozoites dissected from the salivary glands. Numbers of sporozoites in salivary glands were graded 1 + to 4+; total gland ratings = number of + s. * Patients were exposed by mosquito bite or the intravenous (IV) inoculation of sporozaites dissected from the salivary glands. Numbers of sporozoites in salivary glands were graded I + to 4+; total gland ratings = number of +s.
paralytica" , marking the beginning of malaria therapy. As a result of studies on the development of malaria therapy, Wagner-Jauregg was awarded the Nobel Prize for Medicine in 1927.
The first detailed report of laboratory-based malarial studies associated with the treatment of neurosyphilitic patients in England was that of Colonel S. P. James (a member of the Malaria Committee of the League of Nations), and P. G. Shute in 1926.5 Because of objections to induction of malarial attacks by the direct inoculation of blood from patient to patient, they conducted extensive studies at the Horton Mental Hospital in Epsom on the use of bites of plasmodialinfected mosquitoes to induce malaria. The clinical, chemotherapeutic, and immunologic aspects for infections with P. vivax, P. Ja lciparum, P. malariae, and P. ovale in some 2,500 patients observed at the Horton Hospital were reported. [6] [7] [8] [9] Maiariatherapy in the United States. Malaria therapy was first used in the United States at St. Elizabeth's Hospital in Washington, DC in December 1922. In 1926, the South Carolina State Hospital in Columbia initiated studies to standardize malariatherapy of neurosyphilitic patients.lo Beginning in 1931, malaria therapy was routinely used in the treatment of cases of neurosyphilis in the Florida State Hospital in Tallahassee.
II
Kupper12 (1939) published an extensive review of the literature and a detailed summary of the procedures used for the treatment of general paralysis with malaria as was done at the Stati � n for Malaria Research, International Health Division of the Rockefeller Foundation, Florida at the Florida State Hospital in Ta llahassee. It was generally concluded that fever alone was not responsible for the observed beneficial effect; continued parasitemia was also believed to have a beneficial effect on the patients.
Beckerl reported at the time (1949) that induced malaria was indicated as the best method of therapy in paresis, taboparesis, and ocular atrophy. Malariatherapy likewise had a beneficial effect on various types of ocular syphilis, tabes dorsalis with complications, or those forms of syphilis un responsive to chemotherapy. He summarized the possible modes of action that resulted in a beneficial effect following malariatherapy. Fever, even as low as lO2°F, appeared to have a beneficial effect, although this was considered too low to actually kill the spirochetes.!3 Breutsch 14 reported in tensive tissue changes in post-mortem studies on malaria. There was pronounced stimulation of the reticulo-endothelial system, with a marked stimulation of histocytes; a large number of macrophages were found in the perivascular brain tissue, suggesting a phagocytic effect against the spirochete.
Based on an examination of past malariatherapy studies,
Becker' proposed that quartan malaria (P. malariae) be used for malaria therapy of all black patients, white patients reared in malaria-endemic areas, and subjects reared near the Mediterranean Sea. Plasmodium vivax would be used for white patients with no history of previous malaria. It was recommended that P. Ja lciparum should be used only by expert malariologists. He put forth a list of the complications that may develop during malariatherapy and the recom mended treatments. Koop and Solomon's reported the best results in patients who completed 150 hr of fever > lOO°F, whereas Boyd and others 11 found that the best results were when the patients had 21 paroxysms � lO4°F.
In 1931, a laboratory was established in Columbia, South Carolina to maintain malaria parasites for purposes of in fecting patients and to monitor infections in those being treated with malariatherapy. 1 6 Another laboratory was estab lished by the National Institutes of Health at the Georgia State Hospital in Milledgeville, Georgia in March 1946 to provide similar services for the treatment of neurosyphilitic patients. During the period from 1941 to 1954, 1,053 pa tients were treated with malaria in the Columbia hospital; of these, 779 were men and 274 were women; 418 were white and 635 were black Of those treated, 126 patients were con sidered cured and 475 greatly improved.!O The use of malariatherapy for the treatment of neurosyph ilis is an historic procedure that has provided much of the available published evidence for the development of im munity during infection with different malarial parasites. An examination of these publications indicated that during in fection with any of the 4 human-infecting species of Plas modium, parasitologic and clinical immunity develops. An initial increase in parasite count is normally accompanied by episodes of fever (paroxysms). As the infection progresses, the parasite count eventually decreases, and the fr equency and intensity of fever diminishes or disappears, often in the presence of continued parasitemia. In addition, it was ob served that patients who developed immunity to reinfection with the homologous strain of parasite could be reinfected with a heterologous strain. Immunity to infection with one strain of Plasmodium might not give protection to a heter ologous strain of the same species or to another species of parasite. 9,17
The discovery of penicillin materially reduced the number of patients that developed central nervous system syphilis. Parkhurst and Bowman'8 determined changes in cell count, * Parasites/�.d. t a = treatment to cure infection; b = subcurative treatment to modify the primary att�ck; c = subcurative treatment after primary attack; Q = quinine; C = chloroquine; P = chlorguanide; T = bismuth thioglycolate; Am = amodiaquine; Pr = primaquine; Py = pyrimethamine.
total protein, colloidal gold, and Kolmer Wassermann test infected because there were areas of both states where maresults of cerebrospinal fluid in a comparative study of malaria had been endemic. Subsequently, we will report on lariatherapy, hyperthermy treatment, and penicillin. Twelve those patients known to have been previously infected with and 18 months after treatment, penicillin was the most efhomologous and heterologous strains and species of Plasfective treatment.
modium, and the patterns of recrudescence as reported for
Reported here is a retrospective analysis of the combined these patients.1 9-21 records from the Columbia, South Carolina and the Milledgeville, Georgia laboratories on the episodes of fever and
MATERIALS AND METHODS
parasitemia for patients with no recorded previous history of malaria. It is impossible to determine with absolute certainty Patient management. Consent for whatever treatments if none of the patients included here had been previously the hospital staff determined necessary was granted by the * ParasiteS/I·d. t a = treatment to cure infection; b = subcurative treatment to modify the primary attack; c = subcurative treatment after primary attack; Q = quinine; C = chloroquine; P = chlorguanide. :j: Sporozoite-induced infections.
families or the courts when patients were admitted to the hospitals. The decision to treat a neurosyphilitic patient with malaria was made as part of patient care (not for purposes of research) by the medical staff of either the South Carolina State Hospital or the Georgia State Hospital. Patient care and evaluation of clinical endpoints (e.g., fever) were the re sponsibility of the medical staff. During infection, the tem perature, pulse, and respiration were checked every 4 hr and houdy during paroxysms by hospital personnel. During ep isodes of fever (paroxysms), the patients were treated symp tomatically. Infections were terminated at the direction of the attending physician if there was a sudden overwhelming infection with parasites, severe anemia, unremitting pyrexia, rapidly enlarged and tender spleen, extreme exhaustion, car diac disturbances, cyanosis, edema, convulsions, renal dis turbances, marked increase in blood urea, development of another infectious disease, severe jaundice, or rapid debili tation involving weight 10ss. 22 The U. S. Public Health Service (PHS) personnel provided the parasites for inoculation and monitored the daily parasite counts to determine the course of the infection. Mosquito colonies were maintained by the PHS staff for mosquito infection and subsequent transmission to other patients as assigned by the hospital staff. All patients undergoing malariatherapy lived in screened wards of the hospital to prevent possible infection of local anophelines. Treatment. Treatment with non-curative doses of anti malarial drugs (primarily 5 or 10 grains [325 or 650 mg] of quinine sulfate) was often necessary to modify and control the early stages of the infection with P. Ja lciparum. Infec tions were terminated by the use of drugs appropriate for the different parasites, including chloroquine, amodiaquine, quinine, mepacrine, pyrimethamine, proguanil, and prima quine.
Mosquito feeding. Mosquitoes of the species Anopheles quadrimaculatus, An. albimanus, and An. Jre ebomi were al- lowed to feed on patients during periods of gametocytemia to produce mosquito infections for transmission to additional patients. Samples of fed mosquitoes were dissected after ap propriate incubation periods to determine oocyst and/or spo rozoite rates and intensity. Whenever possible, salivary gland dissections were done on all mosquitoes fed on recip ient patients to determine rates and intensity of sporozoites in the donor mosquitoes. Mosquitoes were usually allowed to feed only a single time during inoculation, but on some occasions, multiple interrupted bites were used-usually three bites per mosquito, but occasionally up to 10 bites. On a few occasions, infection was induced by subcutaneous or intravenous injection of sporozoites dissected in sterile fash ion from infected salivary glands. Methods of mosquito rear ing, maintenance, and use in malaria transmission have been described in some detail in previous publications.22 •23 Strains of Plasmodium Ja lciparum. McLendon. The
McLendon strain was isolated in October 1940 from a pa tient who was admitted to the South Carolina State Hospital with malaria.24 . 2 5 El Limon. The EI Limon strain was isolated fr om a resi dent of EI Limon, Transisthmian Highway, Panama in 1948. 26 Santee-Cooper. The Santee-Cooper strain was isolated during the summer of 1946 from a patient living in the vi cinity of the Santee-Cooper impoundments in South Caro lina. 27 Patients were infected either by the intravenous inocula tion of parasitized blood or via sporozoites. With the latter, inoculation was either by the bites of infected mosquitoes or by the subcutaneous or intravenous inoculation of sporozoites dissected aseptically from mosquito salivary glands. In some instances, blood or sporozoites were preserved frozen and were thawed immediately before inoculation into the patient.
Parasitemia. Thick and thin peripheral blood films were made daily by the method of Earle and Perez,28 stained with Giemsa, and examined microscopically for the presence of parasites. The threshold of detection was approximately 10 parasites/v..! . Asexual and sexual parasites were recorded per microliter of blood. During the later stages of the infection, when parasite counts were very low and intermittently neg ative, and no symptoms of malaria were evident, blood films were usually made 2 or 3 times a week.
Data presentation. The parasite counts and fever records from the 2 hospitals have been combined. Most of the re cords made before 1940 were incomplete and were not used. The data presented are based on those records we consider sufficiently complete to be useful. Reported here are data recorded for 318 patients. These patients were infected with P. Ja lciparum for the treatment of paresis and other mental disorders associated with tertiary syphilis. The following data were considered for each patient: 1) the presence of fever � 101°F and � 104°F, 2) parasite counts � 1,000//Ll and �lO,OOO//LI, and 3) the presence of gametocytes � 100/ /LI and � 1,000//Ll for each patient. These parasitologic and fever records were examined to determine the development of immunity following primary malariatherapy. Evidence of developing immunity was the following: 1) reduction of all fever episodes (�101 OF), 2) reduction in severe fever epi sodes (� 104°F), and 3) reduction in days with parasite den- sities 2: 1O,000/f.l.l, and 4) reduction in days of parasite den sities 2: 1,000/f.l.1.
Four different types of infections were considered: 1) spo rozoite-induced infections given antimalarial drugs to mod ify the primary attack, 2) blood-induced infections in which the primary attack was modified by treatment with drugs, 3) sporozoite-induced infections not given antimalarial drugs to modify the primary attack, and 4) blood-induced infections not given antimalarial drugs to modify the primary attack.
Presented graphically are 1) the frequency of fever 2: 101°F and 2: 104°F (number of patients with fever/number of patients remaining in study) for each of the first 100 days of patent parasitemia, 2) the frequency of parasite counts 2: 1,000/f.l.l and 2: 1O,000/f.l.l during the first 100 days of patent parasitemia, and 3) the frequency of gametocyte counts 2: 1oo/f.l.l and 2: 1,000/f.l.l during the first 100 days of patent parasitemia. Prepatent periods for sporozoite-induced infec tions are also plotted.
The days of maximum parasitemia, number of days with fever 2: 101°F and 2: 104°F, number of days of the asexual parasitemia and gametocytemia 2: 10/f.l.l, and number of days of the asexual parasitemia 2: 1O,000/f.l.l and gametocytemia 2: 1,000/f.l.l are presented in tabular form for each of the 318 patients. In addition, the drugs used for modifying or ter minating the infection are listed, For sporozoite-induced in fe ctions, the species of mosquito, the route of inoculation (bites or injection by syringe), the number of mosquito bites, the intensity of the salivary gland infection, and the prepa tent periods are given. The intensity of infection of the sal ivary glands was determined by rating the number of spo rozoites present at dissection as 1 + (1-10 sporozoites), 2+ (11-100 sporozoites), 3+ (101-1,000 sporozoites), or 4+ (> 1,000 sporozoites). The total number of + ratings was then determined.
RESULTS
Patients were divided into 2 major groups. Group I con sisted of 181 patients who received subcurative antimalarial drug(s) during their primary parasitemia to modify the par asite count and/or symptoms, and Group II consisted of 137 patients who received no antimalarial drug treatment during the primary course of parasitemia, Four characteristics of the infections were examined: 1) prepatent period for sporozo ite-induced infections, 2) frequency of fever 2: 101°F and 2: 104°F, 3) frequency of parasitemia 2: 10, 2: 1,000, and 2: 1O,000/f.l.l, and frequency of gametocytemia 2: 10, 2: 100 and 2: 1,000/f.l. Prepatent periods of sporozoite-induced infections. El Limon strain. Fifty-five patients (Table 1) from Groups I and II were infected with the El Limon strain of P. Ja lciparum via sporozoite inoculation. Prepatent periods (Table 1) ranged from 7 to 16 days (mean = 9.8 days, median = 9 days).
Santee-Cooper strain. Thirteen patients were infected with the Santee-Cooper strain of P. Ja lciparum via sporozoite in oculation. Prepatent periods (Table 2 ) ranged from 7 to 14 days (mean = 9,7 days, median = 9 days).
McLendon strain. Forty-one patients were infected with the McLendon strain of P. Ja lciparum via sporozoite inoc ulation. Prepatent periods (Table 3 ) ranged from 9 to 28 days (mean = 13.3 days, median = 13.5 days).
In summary, 109 patients were infected via sporozoites with the El Limon, Santee-Cooper, and McLendon strains of P. Ja lciparum. The prepatent periods for all patients (Fig   ure 1) ranged from 7 to 28 days with a mean and median of 11 days.
Group I-Modified primary attack. Treating of patients with p, Ja lciparum presented the risk of acute malarial dis ease. Thus, as indicated earlier, criteria were established for the administration of subcurative doses of antimalarial drugs t a = treatment to cure infection; b = subcurative treatment to modify the primary attack; c = subcurative treatment after primary attack; C = chloroquine; P = chlorguanide; Py = pyrimethamine; Q = quinine; Am = amodiaquine; Pc = primaquine; A = drug treatment unknown.
that could allow the continuation of the infection with the expected beneficial effect of malarial therapy. In this section, we present data from patients whose primary episodes of parasitemia were modified with subcurative doses of drug.
Seventy-three patients were infected via sporozoite inoc ulation (48 El Limon strain, 23 McLendon strain, and 2 San tee-Cooper strain) and 107 had blood-induced infections (24 EI Limon strain, 22 Santee-Cooper strain, 13 gametocyteless Santee-Cooper strain, and 48 McLendon strain).
Sporozoite-induced infections (fever). El Limon strain.
Forty-eight patients (Table 4) were infected via sporozoites with the El Limon strain of P. Ja lciparum. Fever charts were unavailable for patients 0-289 and 0-322. Of 659 days of fever, 410 (62.2%) occurred during the first 25 days of patent parasitemia, 129 (19.6%) during the 26-50-day period, 56 (8.5%) during the 51-75-day period, and 27 (4. 1%) during the 76-100-day period. Thirty-seven episodes of fever (5 .6%) were recorded during the 101-209-day period. Eight patients had fever beyond day 100; patient 0-279 had fever on day 209.
Santee-Cooper strain. Two patients (Table 5) were infect ed via sporozoites with the Santee Cooper strain of P. Ja l ciparum. Of the 30 episodes of fever, all occurred during the first 25 days of patent parasitemia.
McLendon strain. Twenty-three patients (Table 6) were infected with the McLendon strain of P. Ja lciparum via spo rozoite inoculation. Of the 198 episodes of fever, 135 (68.2%) occurred during the first 25 days of patent parasit emia, 42 (2 1.2%) during the 26-50-day period, 14 (7. 1%) during the 51-75-day period, 6 (3.0%) during the 76-100-day period, and 1 (0.5%) after 100 days. Patient S-41 1 had fever on day 105. Two patients (S-995 and S-1050) had fever on days 56 and 45, respectively; this was after the disap pearance of asexual parasitemia, but during the period when gametocytes were still present.
A total of 73 patients were infected via sporozoites with the EI Limon, McLendon, and Santee-Cooper strains of P. Ja lciparum in which the primary parasitemia was controlled with antimalarial drugs. The frequency of fever during the first 100 days of patent parasitemia ( Figure 2A ) was pri marily concentrated in the first 2-3 weeks.
Sporozoite-induced infections (parasitemia). El Limon strain. Maximum parasitemia (Table 4) ranged from 260 to 222,480/J.L1. The mean length of asexual parasitemia was 126.7 days and the mean length of total parasitemia includ ing gametocytes was 138.8 days. Of the 537 days of high density (:2: 1O,000/J.LI) parasitemia, 29 1 (54.2%) occurred during the first 25 days, 137 (25.5%) occurred during the 26-50-day period, 57 (10.6%) occurred during the 51-75-day period, and 29 (5.4%) during the 76-100-day period. Eight patients had a total of 23 episodes of high-density parasitemia beyond day 100.
Santee-Cooper strain. Two patients (Table 5) were infect ed with the Santee Cooper strain of P. Ja lciparum via spo rozoite inoculation. Prepatent periods were 8 and 9 days. Maximum parasitemia (Table 5) McLendon strain. In 23 patients, maximum parasitemia (Table 6 ) ranged from 940 to 377,520/J.L1. The mean length of asexual parasitemia was 42.8 days and the mean length treatment to cure infection; b = subcurative treatment to modify the primary attack; c = subcurative treatment after primary attack; C = chloroquine; M = mepacrine; P = chlorguanide; Py = pyrimethamine. Am = amodiaquine; Q = quinine; Pr = primaquine; T = bismuth thioglycolate.
of total parasitemia including gametocytes was 52.7 days.
> 50% of the patients had parasite counts � 1,000/jJJ was Of the 92 days of high-density parasitemia, 83 (90.2%) ocday 77. Gametocytes ( Figure 2C ) appeared by the 10th day curred during the first 25 days, 5 (5.4%) occurred during the of patent parasitemia and persisted throughout the first 100 26-50-day period, and 4 (4.3%) occurred during the 51-75-days; high-density gametocytemia (� 1,000IpJ) persisted to day period. day 84. For all patients in this sporozoite-inoculated group, the Blood-induced infections (fever). El Limon strain. Twenfr equency of parasitemia � 1,000 and � 1O,0001,.1l during ty-four patients (Table 7) were infected with the EI Limon the first 100 days of patent parasitemia (Fig. 2B) showed a strain of P. Ja lciparum via inoculation of parasitized blood. primary peak that was interrupted with drug treatment and There were 248 episodes of fever for 23 patients. Of these, a longer sustained period of parasite counts > 1,000hll from 187 (75.4%) occurred during the first 25 days, 46 (18.5%) approximately day 15 through day 50. The last day on which during the 26-50-day period, 12 (4.8%) during the 51-75- day period, and 3 (1.2%) during the 76-100-day period. No fever record was available for patient G-238 and during the first 5 days for patient G-207 .
Santee-Cooper strain. Twenty-three patients (Table 5) were infected with the gametocyte-producing Santee-Cooper strain of P. Ja lciparum via inoculation of parasitized blood.
There were 175 episodes of fever in 21 patients (no fever record was available for patients G-238 and G-195). Of these, 155 (88.6%) occurred during the first 25 days and 20 (11.4%) during the 26-50�day period. One patient (G-121) experienced no episodes of fever.
Santee-Cooper-gametocyteless strain. Thirteen patients (Table 5) were infected with the gametocyteless Santee-Coo per strain of P. Ja lciparum via inoculation of parasitized blood. There were 191 episodes of fever among the 13 pa tients. Of these, 138 (72.3%) occurred during the first 25 days, 40 (20.9%) during the 26-50-day period, 9 (4.7%) dur ing the 51-75-day period, and 3 (1.6%) during the 76-100-day period. Fever occurred on day 133 in patient G-280.
McLendon strain. Forty-eight patients (Table 8) were in fected with the McLen�on strain of P. Ja lciparum via inoc ulation of parasitized blood. Fever charts were unavailable for patients G-167 and S-392. There were 676 episodes of fever for the remaining 46 patients. Of these, 428 (64.3%) occurred during the first 25 days, 154 (23.1%) during the 26-50-day period, 80 (12.0%) during the 51-75-day period, and 8 (1.2%) during the 76-100-day period. Six fevers (0. 1 %) occurred after the 100-day period.
A total of 104 patients infected via parasitized erythro cytes with the EI Limon, McLendon, and Santee-Cooper strains of P. Ja lciparum had records of fe vers. The frequency of fever during the first 100 days of patent parasitemia (Fig  ure 3A) exceeded 50 percent until day 11 and thereafter decreased. The last fever was on day 98.
Blood-induced infections (parasitemia). El Limon strain.
Maximum parasitemia (Table 7) ranged from 18,350 to 476,440J,..t.l . The mean length of asexual parasitemia was 91.5 days and the mean length of total parasitemia including gametocytes was 107 days. Of the 406 days of high-density parasitemia, 327 (80.5%) occurred during the first 25 day period, 57 (14.0%) during the 26-50-day period, 19 (4.7%) during the 51-75-day period, and 3 (0.7%) during the 76-100-day period.
Santee-Cooper strain. Maximum parasitemia (Table 5) ranged fr om 8,064 to 503,286/1.t.l. The mean length of asex ual parasitemia was 90.3 days and the mean length of total parasitemia including gametocytes was 101.5 days. Of the 237 days of high-density parasitemia, 212 (89.5%) occurred during the first 25 days and 25 (10.5%) during the 26-50-day period.
Santee-Cooper-gametocyteless strain. Maximum parasit emia (Table 5 ) ranged from 59,040 to 342,720/1).1. The mean length of asexual parasitemia was 123.3 days. Of the 175 days of high-density parasitemia, 107 (6 1.1 %) occurred dur ing the first 25 days, 42 (24.0%) during the 26-50-day pe riod, 20 (11.4%) during the 51-75-day period, and 6 (3.4%) during the 76-1 00-day period.
McLendon strain. Maximum parasitemia (Table 8 ) ranged from 9,250 to 265,000/ ILL The mean length of asexual par asitemia was 71.5 days and the mean length of total para sitemia including gametocytes was 85.9 days. Of the 338 days of high-density parasitemia, 262 (77.5%) occurred dur ing the first 25 days, 51 (15.1%) during the 26-50-day pe riod, 20 (5.9%) during the 51-75-day period, and 5 (1.5%) during the 76-100-day period.
For 108 patients in this blood-induced group, the frequen cy of asexual parasitemia :::: : 1,000/1L1 and :::: : 10,000/1L1 dur ing the first 100 days of patent parasitemia ( Figure 3B ) showed a primary peak that was interrupted with drug treat ment and a secondary period of parasite counts > 1,000/1L1 from day 25 through day 46. Garhetocytes ( Figure 3C ) in those patients infected with the gametocyte-producing strains appeared as early as seventh day of patent parasitemia and persisted throughout the first 100 days; high-density ga metocytemia (:::: : 1,000/ILI) persisted to day 96.
Group II-Primary attack not modified with drugs. This group of patients had clinical and parasitologic responses that did not require early intervention with subcurative an timalarial drugs. It is possible that some of the patients may have had previous malaria infections at some time before admission although there were no records to indicate this.
Forty patients were infected via sporozoite inoculation (12 EI Limon strain, 10 Santee-Cooper strain, and 18 McLendon strain), and 97 patients had blood-induced infections (9 EI TABLE 9 Maximum parasitemia, days of fever (2: 101°F and 2:104°F), and days of parasitemia in 12 sporozoite-induced and 9 blood-induced infections with the El Limon strain of Plasmodium Ja lciparum in patients with no previous history of infection and not treated to modify primary attack McLendon strain. Eighteen patients (Table 11) had 181 episodes of fever during the first 100 days of patent parasit emia. Of these, 144 (79.6%) occurred during the first 25 days, 20 (11.0%) during the 26-50-day period, 13 (7 .2%) during the 51-75-day period, and 4 (2.2%) during the 76-100-day period. In summary, 40 patients were infected via sporozoites with the El Limon, Santee-Cooper, and McLendon strains of P. Ja lciparum. Fever charts were available for 38 of these.
The fever during the first 100 days of patent parasitemia for these patients ( Figure 4A ) was primarily concentrated in the first 2 weeks and rapidly diminished. The last fever 2: 101°F was on day 99.
Sporozoite-induced infections (parasitemia). El Limon strain. Maximum parasitemia in 12 patients (Table 9 ) ranged from 7,500 to 172,800/J..l 1. The mean length of asexual par asitemia was 167.8 days and the mean length of total para sitemia including gametocytes was 176.3 days. Of the 108 days of high density parasitemia, 74 (68.5%) occurred dur ing the first 25 days, 19 (17.6%) occurred during the 26-50-day period, and 15 (13.9%) occurred during the 51-75-day period.
Santee-Cooper strain. Maximum parasitemia (Table 10) in 10 patients ranged from 13,860 to 181,440/J..l 1. The mean length of asexual parasitemia was 184.7 days and the mean length of total parasitemia including gametocytes was 209.3 days. Of the 72 days of high-density parasitemia, 68 (94.4%) occurred during the first 25 days, and 4 (5.6) occurred during the 26-50-day period.
McLendon strain. Maximum parasitemia (Table 11) in 18 patients ranged from 2,400 to 83,000/J..l 1. The mean length of asexual parasitemia was 88.7 days and the mean length of total parasitemia including gametocytes was 92.6 days. Of the 75 days of high-density parasitemia, 72 (96.0%) oc curred during the first 25 days, and 3 (4.0%) occurred during the 26-50-day period.
In summary, 40 patients with no previous history of ma laria were infected via sporozoites with the El Limon, San tee-Cooper, and McLendon strains of P. Ja lciparum. High density parasitemia ( Figure 4B ) was concentrated in the first 2 weeks of patent parasitemia although parasite counts 2: 1,000/J..l l continued to be frequent through the first 75 days of patent parasitemia. Gametocytes ( Figure 4C ) appeared as early as the ninth day of patent parasitemia and persisted throughout the first 100 days; high-density gametocytemia (2: 1,000/J..l l) was last recorded on day 84.
Blood-induced infections (fever). El Limon strain. Nine patients were infected with the El Limon strain of P. Ja lci parum via inoculation of parasitized blood (Table 9 ). Fever records were complete for 8 of these and indicated 90 epi- Santee-Cooper strain. Twenty-seven patients were infected with the Santee-Cooper strain of P. Ja lciparum via inoculation of parasitized blood (Table 10) . Twenty-four of these had fever records; there were 144 episodes of fever. Of these, 136 (94.4%) occurred during the first 25 days, 7 (4.9%) during the 26-50-day period, and 1 (0.7%) during the 51-75-day period. No fever records were available for 3 of the patients.
Santee-Cooper-gametocyteless strain. Eight patients were 0  32  0  90  18  63  6  C,  93  10  93  12  100  13  79  1  107  0  103  0  Q'  121  8  149  0  149  14  183  12  Q a  208  17  98  22  21 1  3  209  12  C,  218  5  222  11  232  10  205  26  240  7  257  9  250  6  161  10  332  9  212  10  414  41  343  11  328  22  184  11  65  6  0  0  C,  109  22  0  0  C"  149  6  0  0  C'  152  8  0  0  C"  252  15  0  0  306  9  0  0  C'  375  4  0  0  417  15  0  0 infected with the gametocyteless Santee-Cooper strain of P. Ja lciparum via inoculation of parasitized blood (Table 10) .
Seven patients had 93 episodes of fever. Of these, 80 (86.0%) occurred during the first 25 days, 7 (7.5%) during the 26-50-day period, 5 (5.4%) during the 51-75-day period, and 1 (1.1 %) during the 76-100-day period. No fever record was available for patient G-256.
McLendon strain. Fifty-three patients (Table 11) were infected with the McLendon strain of P. Ja lciparum via inoculation of parasitized blood. The 53 patients had 657 episodes of fever. Of these, 507 (77.2%) occurred during the first 25 days, 96 (14.6%) during the 26-50-day period, 42 (6.4%) during the 51-75-day period, and 11 (1.7%) during 115  8  130  13  132  2  43  0  134  7  24  0  147  21  92  0  157  3  37  0  182 12 52 0 t a = treatment to cure infection; c = subcurative treatment after primary attack; C = chloroquine; Q = quinine; P = chlorguanide; T = bismuth thioglycolate; Py = pyrimethamine. =1= Sporozoite-induced infection. § Observations ceased at day 67.
the 75-100-day penod. One patient (S-439) also had fever on day 104. In summary, 97 patients were infected via infectious blood with the EI Limon, Santee-Cooper, and McLendon strains of P. Ja lciparum. The fr equency of fever during the first 100 days of patent parasitemia for 93 of these patients 4 . Frequency of fever, asexual parasitemia, and game tocytemia during the first 100 days in patients with sporozoite-in duced infections with the EI Limon, Santee-Cooper, and McLendon strains of Plasmodium Ja lciparum. A, frequency of fever (2 101°F and 2 104°F). B, frequency of asexual parasitemia 2 1,000hd and 2 10,000/ILI. C, frequency of gametocytemia 2 100/lLl and 2 1,000/ ILl. Patients were not given subcurative doses of antimalarial drugs to modify the primary attack.
( Figure 5A ) was concentrated in the first 2 weeks and then rapidly decreased.
Blood-induced infections (parasitemia). El Limon strain.
In 9 patients, maximum parasitemia (Table 9 ) ranged from 25,560 to 200, 1 601jl.1. The mean length of asexual parasit emia was 129.7 days and the mean length of total parasit- Santee-Cooper strain. In 27 patients, maximum parasit emia (Table 10 ) ranged from 1,016 to 385,920/J.L1. The mean length of asexual parasitemia was 131.6 days and the mt;?an length of total parasitemia including gametocytes was 138.6 days. Of the 240 days of high density parasitemia, 190 (79.2%) occurred during the first 25 days, 33 (13.8%) during the 26--50-day period, 14 (5.8%) during the 51-75-day pe riod, and 1 (0.4%) during the 76--100-day period. Patient G-48 had high-density parasitemia on days 196 and 198.
Santee-Cooper-gametocyteless strain. In 8 patients, max imum parasitemia (Table 10 ) ranged from 29,280 to 96,480/ J.L1. The mean length of asexual parasitemia was 228.3 days. Of the 83 days of high-density parasitemia, 67 (80.7%) oc curred during the first 25 days, 7 (8.4%) during the 26 to 50 day period, 8 (9.6%) during the 51 to 75 day period, and 1 (1.2%) on day 122 (patient G-268).
McLendon strain : In 53 patients, maximum parasitemia (Table 11) ranged from 120 to 168,840 per J.L1. The mean length of asexual parasitemia was 79. 1 days and the mean length of total parasitemia including gametocytes was 81.7 days. Of the 273 days of high-density parasitemia, 244 (89.4%) occurred during the first 25 days, 16 (5.9%) oc curred during the 26-50-day period, and 13 (4.8%) during the 51-75-day period.
In summary, 97 patients with no previous history of ma laria were infected via trophozoites with the EI Limon, San tee-Cooper, and McLendon strains of P. Ja lciparum and re quired no drug modification of the primary parasitemia. High-density parasitemia ( Figure 5B ) was concentrated in the first 2 weeks of patent parasitemia although parasite counts � 1,OOO/J.LI continued to be frequent through the first 75 days of patent parasitemia. Gametocytes ( Figure 5C ) ap peared as early as the eighth day of patent parasitemia. The percentage of patients with gametocyte counts � 100/J.LI de creased markedly by day 38; high-density gametocytemia (� 1,000/I.d) persisted until day 96.
DISCUSSION
There were two major objectives in conducting a retro spective analysis of clinical and parasitologic parameters as sociated with induced P. Ja lciparum in humans: 1) to doc ument the initial clinical and parasitologic response and the subsequent development of clinical and parasitologic im munity in humans infected with P. Ja lciparum, and 2) to determine the effect of previous homologous and heterolo gous malaria on subsequent infection with this parasite. This first report concerns those patients with no previous known history of malarial infection, although a retrospective anal ysis indicated 2 basic groups of patients, those requiring sub curative doses of antimalarial drugs during their primary at tack and those able to contain sustained infections without such intervention.
The prepatent periods as reported here showed a relatively large variation in the interval between sporozoite challenge and the first appearance of parasites as determined by thick blood film examination. Prepatent periods are assumed to be governed by the size of the challenge sporozoite inoculum. However, it was difficult to predict prepatent periods based on the number of infective bites or the intensity of the sal ivary gland infections. Previous studies8 have shown that prepatent periods in all these strains studied were materially reduced by an increase in the number of infective bites used to induce infection.
Fever was the primary indicator of clinical malaria. Fever, particularly the higher intensity of fevers � 104°F, was gen erally concentrated in the first 25 days of patent parasitemia. Thus, clinical immunity was apparent within approximately 3 weeks, although many patients sustained parasite counts � 1,OOO/J.LI and intermittent low-grade fever for extended periods.
It was somewhat surprising that many of the patients were able to control their parasitemia without the administration of antimalarial drugs. In those who were treated, small doses of quinine (5-10 grains) were usually sufficient to provide at least temporary control of the infection, pending devel opment of immunity sufficient to protect the patient fr om the more adverse effects of the infection without terminating completely parasitemia or fever. Because it was believed that parasitemia, in addition to fever, was beneficial for the treat ment of patients with neurosyphilis, many infections were allowed to continue after fever no longer occurred. Thus, the long-term course of parasitemia could be characterized and documented, as well as the frequency of recrudescences with accompanying fever and higher-density parasite counts.
An examination of the combined fever patterns for all patients suggested that those given antimalarials to modify the infection had a slightly higher frequency of fever > 101°F. When the number of fever episodes during the first 100 days was tabulated for each group of patients, there were 0.2296 fevers per day in those treated and 0. 1352 fevers per day in those not treated. With regard to parasite counts of 1,000/J.LI or more, those requiring treatment had 0.3383 par asite days > 1,000/J.LI during this period compared with 0.3335 parasite days for those not treated. With regard to gametocyte densities of 100/J.LI or more, those requiring treatment had 0.2269 gametocyte days > 100/J.LI compared with 0.2216 gametocyte days for those not treated.
High-density parasite counts were concentrated in the first 2-3 weeks of detectable parasitemia. However, parasitemia, including garnetocytemia, persisted for extended periods in the patients.
In subsequent reports, 19-2 1 we will present similar fever and parasite data from patients reinfected with homologous and heterologous strains of P. Ja lciparum, and patients pre viously infected with P. vivax, P. ovale, and P. malariae. It is hoped that these data will be useful in understanding and predicting the development of clinical and parasitologic im munity following infection with P. Ja lciparum, and assist in the evaluation of candidate antimalaria vaccines.
